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The lipid phosphatidylinositol-3-phosphate (PI3P) is a regulator of two fundamental but
distinct cellular processes, endocytosis and autophagy, so its generation needs to be under
precise temporal and spatial control. PI3P is generated by two complexes that both contain
the lipid kinase VPS34: complex II on endosomes (VPS34/VPS15/Beclin 1/UVRAG), and
complex I on autophagosomes (VPS34/VPS15/Beclin 1/ATG14L). The endosomal GTPase
Rab5 binds complex II, but the mechanism of VPS34 activation by Rab5 has remained elusive,
and no GTPase is known to bind complex I. Here we show that Rab5a–GTP recruits endocytic
complex II to membranes and activates it by binding between the VPS34 C2 and VPS15
WD40 domains. Electron cryotomography of complex II on Rab5a-decorated vesicles shows
that the VPS34 kinase domain is released from inhibition by VPS15 and hovers over the lipid
bilayer, poised for catalysis. We also show that the GTPase Rab1a, which is known to be
involved in autophagy, recruits and activates the autophagy-specific complex I, but not
complex II. Both Rabs bind to the same VPS34 interface but in a manner unique for each.
These findings reveal how VPS34 complexes are activated on membranes by specific Rab
GTPases and how they are recruited to unique cellular locations.
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VPS34 is the primordial member of the phosphoinositide 3-kinase (PI3K) family of lipid kinases, and it is present inall eukaryotic clades. It phosphorylates phosphatidylino-
sitol (PI) to generate PI3P, which controls a range of cellular
processes by reversibly recruiting specific protein effectors to
membranes. Stable membrane association of effector proteins, as
well as the VPS34 complexes themselves, is often achieved by a
combination of low-affinity membrane interactions and an
additional determinant, such as a small GTPase1. The Rab family
of small GTPases are fundamental to intracellular membrane
trafficking in which organelles exchange proteins and lipids in an
intricate network of vesicular transport. Furthermore, many viral
and bacterial pathogens exploit Rabs for entry and survival2–6,
and Rab misregulation is associated with human diseases such as
neurodegeneration and cancer7–11. Rab5 is indispensable at early
endosomes12, where it has a role in the activation of VPS3413.
PI3P positively regulates the activity of Rab5 by recruiting it to
membranes through a positive feedback loop with its GEF/
effector complex, Rabex5/Rabaptin514. Human VPS34 forms two
heterotetrameric core complexes known as complexes I and II15.
Complex I is composed of VPS34, VPS15, Beclin 1, and ATG14L,
whereas complex II has UVRAG instead of ATG14L. This dif-
ference in a single subunit determines how and where the two
complexes are active. Complex I produces PI3P at the phago-
phore, promoting autophagosome formation, while complex II
has a main role in endocytic sorting15–17, along with other cel-
lular pathways18–20. Complexes I and II uniquely respond to the
nature of the lipid membranes in which they find their sub-
strates21. However, the broader interaction of the entire complex
with membranes and membrane-associated proteins remains
unclear. Furthermore, although VPS34 and VPS15 were identified
as Rab5 interactors, the mechanism of activation has remained
elusive for over 20 years13,22.
Here we show that Rab5a recruits and profoundly activates
endocytic complex II on membranes, using unnatural amino acid
(UAA) mediated cross-linking, hydrogen/deuterium exchange
mass spectrometry (HDX-MS), electron cryotomography (cryo-
ET), and a reconstituted kinase assay. Our cryo-ET structure of
complex II bound to Rab5a-decorated membranes shows how the
complex directly engages with the membrane and how it is
activated by Rab5a. We also find that the GTPase Rab1a is an
exclusive activator of the autophagy-specific VPS34 complex I but
not complex II.
Results
Rab5a is a potent activator of complex II. We first examined the
effect of membrane-anchored Rab5a on the lipid kinase activity of
human VPS34 complexes on giant unilamellar vesicles (GUVs).
In cells, Rab5 is C-terminally prenylated, and this modification
anchors the GTPase on endosomal membranes23. In order to
mimic membrane attachment, Rab5a (Q79L), loaded with either
GDP or GTP, was coupled to GUVs through a covalent bond
between the C-terminal cysteine and a maleimide-conjugated
lipid in the membrane (Supplementary Fig. 1a). The immobilised
Rab5a potently activated complex II up to 40-fold in a GTP-
dependent manner (Fig. 1a), but activated complex I only mod-
estly by threefold (Fig. 1b). Soluble Rab5a–GTP had no influence
on the activity of VPS34 complexes (Supplementary Fig. 1b).
Rab5a-GDP coupled to GUVs showed only a modest activation of
complex II (threefold) (Fig. 1a) and no activation of complex I
(Fig. 1b). Vesicle flotation assays showed that 100 nm large uni-
lamellar vesicles (LUVs) containing membrane-anchored
Rab5a–GTP efficiently recruited complex II to membranes in a
GTP-dependent manner (Fig. 1c and Supplementary Fig. 2a) but
less-efficiently recruited complex I (Supplementary Fig. 2b).
Taken together, these results show that recruitment of VPS34
complex II to membranes by Rab5a is GTP-dependent and
essential for the activation of the complex.
Mapping the Rab5a–GTP binding site on complex II. To map
the Rab5a–GTP interaction site on complex II, we first employed
crosslinking by genetic code expansion. Rab5a (Q79L) with an
amber mutation was coexpressed with the bromoalkyl-bearing
unnatural amino acid BrCO6K and an orthogonal pyrrolysyl-
tRNA synthetase/tRNA pair in bacteria (Fig. 1d)24. BrCO6K is a
lysine derivative that can crosslink to proximal nucleophilic
amino acids such as cysteines, aspartates and glutamates to bridge
distances up to 15 Å under physiological conditions24,25. A Rab5a
mutant, in which the codon for S84 in switch 2 was replaced
by the amber codon, showed the most efficient crosslinking
(Fig. 1d). Both complex II and VPS34 alone incubated with
Rab5a–GTP–BrCO6K gave rise to a crosslinked product that ran
slightly above the 120 kDa molecular weight marker, consistent
with 102 kDa VPS34 crosslinked to the 24 kDa Rab5a (126 kDa).
Rab5a crosslinked much more efficiently to complex II than to
VPS34 alone, suggesting that VPS15, Beclin 1 or UVRAG also
influence the Rab5a–GTP interaction. Analysis by mass spectro-
metry of the crosslinked products identified Rab5a residue 84
crosslinked to VPS34 E202 (Supplementary Table 1). Residue
E202 is near the C-terminal end of helix α2 in the helical hairpin
insertion (C2HH) in the VPS34 C2 domain (Fig. 1e).
The crosslinking results were further confirmed by HDX-MS of
complex II in the presence and absence of Rab5a (Q79L) loaded
with GTP (Fig. 1e and Supplementary Fig. 3a, Supplementary
Data 1). A stretch of helix α2 in the VPS34 C2HH insertion
(HDX 204–206) showed a decrease in HDX. Furthermore, a
reduction in deuterium incorporation was seen in VPS15 in the
WD40 domain (HDX 1213–1224 and 1278–1299) and in a small
globular domain in VPS15 (HDX 771–787) that we will refer to as
the VPS15 SGD (the domain consisting of residues 771–816).
Combined with the observed BrCO6K crosslinks, we could make
a model for the Rab5a–GTP interaction in which Rab5a binds to
a tripartite binding site made of the VPS34 C2HH insertion, the
VPS15 SGD domain and the WD40 domain (Fig. 1e and
Supplementary Fig. 3a).
In order to validate the importance of the observed VPS34/
Rab5a interface, we assayed complex II recruitment by Rab5a in
cells. mCherry-tagged Rab5a-Q79L transfected into HEK293T
cells caused Rab5a-positive enlarged endosomes as expected
(Fig. 2a–d)26,27. VPS34-EGFP cotransfected along with the other
complex II components (VPS15, Beclin 1, UVRAG), colocalized
with mCherry–Rab5a–Q79L (Fig. 2a, e). We next tested the
importance of the C2HH in VPS34 for binding Rab5a by
mutating C2HH residues 199-REIE-202 to alanine (REIE >
AAAA). Surprisingly, Rab5a colocalization was markedly
increased with complex II carrying VPS34 REIE > AAAA (Fig. 2b,
e). No colocalization with Rab5a was observed with complex I
when VPS34-EGFP (WT or REIE > AAAA) was cotransfected
along with VPS15, Beclin 1, and ATG14L (Fig. 2c–e). This
mutation has a similar effect in vitro, with complex II REIE >
AAAA being activated by Rab5a–GTP fourfold more than the
wild-type (Fig. 2f, g).
Rab1 interacts with and activates the autophagy-associated
complex I. While Rab5 is a long-known effector of VPS34, we
wanted to know whether there are other Rab GTPases that directly
interact with and regulate VPS34 complexes. We recently carried
out a MitoID analysis, which uses proximity biotinylation to
identify effectors bound to a mitochondrially-localised form of 11
human Rab GTPases28. As expected, we found VPS34 and VPS15
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amongst the top Rab5-interacting proteins. Here, we expand the
MitoID analysis to include Rab1a. Surprisingly, among the identi-
fied proteins, we detected all four subunits of VPS34 complex I, but
not the UVRAG subunit characteristic for complex II (Fig. 3a). The
in vitro kinase assay with Rab1a-decorated GUVs showed that
Rab1a–GTP potently activates complex I by 11-fold while
Rab1a–GDP only activates by threefold (Fig. 3b). In contrast,
membrane-bound Rab1a loaded with either GTP or GDP has no
influence on complex II activity (Fig. 3c). Consistent with this, a
flotation assay showed that Rab1a-coupled to LUVs efficiently
recruited complex I to membranes in a GTP-dependent manner
(Fig. 3d and Supplementary Fig. 2c), while it did not recruit com-
plex II (Supplementary Fig. 2d). Differences in HDX between
complex I in the presence and absence of Rab1a (Supplementary
Data 2) indicated that helix α2 (HDX 194–200 and 204–214) from
the VPS34 C2 domain is in contact with Rab1a (Fig. 3e and Sup-
plementary Fig. 3b), suggesting that Rab1a is likely to bind in the
same pocket on complex I as Rab5a on complex II. In contrast to
Rab5a-complex II, the VPS15 SGD and the WD40 domain did not
show significant HDX reduction, whereas the Beclin 1 coiled-coil
domain 2 (CC2, HDX 223–235) shows a significant HDX increase
(Fig. 3e).
Consistent with previous reports of Rab1 on the Golgi
apparatus29,30, GTP-locked mCherry-Rab1a–Q70L shows a
juxtanuclear localisation (Fig. 4a–d). When wild-type VPS34-
EGFP was cotransfected with the other components of complex I,
it strongly colocalised with this compartment (Fig. 4a, e). On the
other hand, VPS34 complex I carrying the REIE > AAAA
mutation showed a markedly reduced colocalization with
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Fig. 1 Membrane-bound Rab5a–GTP recruits and activates VPS34 complex II. a, b GUV-based activity with membrane-tethered Rab5a. The reaction
progress curves and initial rates are shown. Micrographs: AF647-PX signals at the end of reactions. Scale bars: 5 μm. Bar graphs: initial rates of the reaction
curves (AF647-PX fluorescence change/min in arbitrary units, AU). a Complex II is greatly activated by membrane-tethered Rab5a in a GTP-dependent
manner. b Complex I is only modestly activated by membrane-attached Rab5a–GTP. c Complex II is recruited to Rab5a-decorated LUVs in a GTP-
dependent manner as measured by a flotation assay. Here, complex II is mixed with LUVs and the mixture is added on top of a sucrose gradient and
centrifuged. Membrane-bound proteins float up to the top of the gradient as seen in gel lanes (Top). Gel quantification can be found in Supplementary
Fig. 2a. d Mapping the Rab5a–GTP binding site by proximity-triggered crosslinking of complex II. SDS-PAGE gel of crosslinking reactions, products
indicated by green arrows. e Mapping the Rab5a binding site on complex II by the HDX-MS. HDX changes are displayed on a model of human complex II
created with PyMOL. Rab5a binding protects (coloured in cyan and blue) the VPS34 C2 helical hairpin insertion (C2HH) and the VPS15 SGD and WD40
domains. The VPS34 C2 (E202) that is crosslinked by unnatural amino acid Rab5a-84BrCO6K is coloured green and shown in an expanded panel. Source
data are provided as a Source Data file.
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or REIE > AAAA) could not be recruited to this compartment
(Fig. 4c–e). Consistent with the cellular data, complex I with
VPS34 REIE > AAAA mutation was not activated by GUVs
coated with Rab1a–GTP, again showing that the liposome activity
assay faithfully recapitulates the recruitment of the complexes to
membranes in cells (Fig. 4f, g).
The cryo-ET structure of complex II on Rab5a–GTP-coupled
vesicles. Complexes I and II form a Y-shaped structure: a catalytic
arm bearing the kinase domains of VPS34 and VPS15 at its tip
and an adaptor arm with Beclin 1 and either UVRAG or ATG14L
supporting the VPS15/VPS34 subunits31–34. Several structures of
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Fig. 2 The C2 helical insertion (C2HH) of VPS34 is a critical element for the interaction of complex II with Rab5a. a, b GTP-locked Rab5a (Q79L) and all
four components of complex II, containing either C-terminally EGFP-tagged WT (a) or C2HH mutant REIE > AAAA VPS34 (b), were coexpressed in
HEK293T cells. Confocal images show cellular localisation of mCherry–Rab5a-Q79L (magenta) and VPS34-EGFP (cyan). To the right of each panel, traces
for the fluorescence along the transect indicated by the line in the micrograph are shown. The C2HH REIE mutant markedly increased colocalization of
complex II with Rab5a (b, e) compared to VPS34 WT (a, e). c, d GTP-locked Rab5a (Q79L) and all four components of complex I, containing either C-
terminally EGFP-tagged WT (c) or mutant REIE > AAAA VPS34 (d), were coexpressed in HEK293T cells. The mutant had no impact on the colocalization
of complex I with Rab5a (c–e), quantitated as described in methods. Error bars: standard deviation. ***: p < 0.0001; n.s.: p > 0.05. Scale bars: 10 μm. f GUV
assay of activity of complex II shows that the VPS34 C2HH REIE > AAAA mutation greatly potentiates the activation of complex II by Rab5a–GTP, without
affecting the basal activity of complex II. Micrographs: AF647-PX signals at the end of reactions. Scale bars: 5 μm. g The initial rates in the GUV assay in
f (AF647-PX fluorescence change/min in arbitrary units, AU) are depicted. ***: p < 0.001; n.s.: p > 0.05. Source data are provided as a Source Data file.
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these structures directly reveal how these complexes interact with
membranes. In order to directly visualise the interaction with
membranes, we determined the structure of complex II bound to
Rab5a–GTP-decorated LUVs using cryo-ET and subtomogram
averaging. To improve the membrane recruitment, we made a
construct (complex II–BATS) that has the C terminus of UVRAG
deleted (residues 1–464 remaining) and replaced by the BATS
domain of ATG14L (residues 413–492)21,36 which can still be
activated by Rab5a–GTP (Supplementary Fig. 4a). We collected
115 tilt series on a Titan Krios electron microscope, of which 105
were used for subtomogram averaging. Subtomograms for aver-
aging were picked from 3008 vesicles with a mean diameter of
81.3 nm and a standard deviation of 19.5 nm (Fig. 5a and
Supplementary Fig. 4b). A total of 26,979 subtomograms con-
tributed to the final average resulting in a reconstruction with an
overall resolution of 9.8 Å (Fig. 5b and Supplementary Fig. 5).
Several studies of membrane coat proteins such as COP-I/II,
retromer or clathrin have been determined using subtomogram
averaging37–40. Coat proteins assemble into symmetric lattice
structures whereas complex II is distributed irregularly over the
membrane surface and is randomly rotated.
Rab5a binds to a tripartite site made of VPS34 and VPS15 on
the adaptor arm of complex II. A model of human complex II
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50 nM Complex I + Rab1a-GTP (n=24)
50 nM Complex I + Rab1a-GDP (n=23)




Fig. 3 Rab1a is a specific activator of VPS34 complex I. a Immunoblot of streptavidin precipitates from cells in which MitoID had been carried out for
Rab1a WT, QL, and SN mutants (left) or Rab5 QL (right). Rab1a interacts specifically with components of complex I (VPS34, VPS15, Beclin 1, ATG14L) but
not with the complex II-specific UVRAG. Rab5a shows only a weak interaction with the complex I-specific ATG14L. b Complex I was potently activated by
membrane-attached Rab1a in a GTP-dependent manner. c No activation of complex II by either membrane-attached Rab1a–GTP or Rab1a–GDP was
detected. b, c Micrographs: AF647-PX signals at the end of reactions. Scale bars: 5 μm. Bar graphs: initial rates of the reaction curves. d Lipid flotation
assays showing complex I recruitment to Rab1a-decorated membranes in a GTP-dependent manner. Gel quantification is in Supplementary Fig. 2c.
eMapping Rab1a binding site on complex I by HDX-MS. Rab1a binding increases protection (coloured in cyan and blue) of the VPS34 C2 insertion (C2HH)
and decreases protection (coloured yellow and red) of Beclin 1 CC2. Source data are provided as a Source Data file.
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SWISSMODEL41. This model could generally be fit as a
rigid body into the cryo-ET reconstruction, and this was fol-
lowed by small manual adjustments and refinement with
REFMAC42–45 and ISOLDE46 (Fig. 5b). Examination of the
cryo-ET density revealed a clear extra density at the adaptor
arm that could not be allocated to any of the complex II
components. The density is located exactly where Rab5a was
positioned by HDX-MS and UAA crosslinking analysis
(Fig. 1e) and was of sufficient resolution to unambiguously fit
the crystal structure of Rab5a–GMP–PNP (PDB 3MJH47)
(Fig. 5c and Supplementary Movie 1). Thus, Rab5a–GTP is
located in a pocket surrounded by the VPS15 SGD and WD40
domain, the UVRAG/Beclin 1 coiled-coil, and VPS34 C2HH
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WT VPS34-EGFPmCherry-Rab1a (Q70L) MERGE
Complex I transfected
Complex I transfected
Fig. 4 The VPS34 C2HH is also a critical element for the interaction of complex I with Rab1a. a, b GTP-locked Rab1a (Q70L) and all four components of
complex I, containing either C-terminally EGFP-tagged WT (a) or mutant REIE > AAAA VPS34 (b), were coexpressed in HEK293T cells. Confocal images
show the localisation of mCherry-Rab1a–Q70L (magenta) and VPS34-GFP (cyan). The REIE mutant in VPS34 reduces colocalization of complex I with
Rab1a (e, quantitated as described in ‘Methods’ section). c, d GTP-locked Rab1a (Q70L) and all four components of complex II, containing either C-
terminally EGFP-tagged WT (c) or mutant REIE > AAAA VPS34 (d), were coexpressed in HEK293T cells. Complex II shows no significant colocalization
with Rab1a for either WT or mutant VPS34 (e, quantitated as described in the methods. Error bars: standard deviation. ***: p < 0.0001; n.s.: p > 0.05). Scale
bars: 5 μm. f GUV assay of activity of complex I shows that the VPS34 C2HH REIE > AAAA mutation eliminates activation of complex I by Rab1-GTP,
without affecting the basal activity. Micrographs: AF647-PX signals at the end of reactions. Scale bars: 5 μm. g The initial rates in the GUV assay (AF647-
PX fluorescence change/min in arbitrary units, AU) in f are depicted. ***: p < 0.001; n.s.: p > 0.05. Source data are provided as a Source Data file.
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Capturing complex II in its activated state. In the crystal
structure of yeast complex II, the Vps34 activation loop and the
C-terminal helix, two elements critical for the lipid kinase activity
of Vps34, are packed against the N-lobe of the kinase domain of
Vps15, and we and others proposed that this represents an
autoinhibited conformation31,34 (Fig. 5d). As noted above, the
cryo-ET density of the catalytic arm could not precisely accom-
modate the model of the inactive yeast complex II. Instead, it
appears that binding to Rab5a-decorated membranes releases the













S. cerevisiae complex II






















VPS34 kinase activation loop
VPS15 kinase N-terminus
Fig. 5 Cryo-ET structure of VPS34 complex II on Rab5a–GTP-coated membranes. a Section through a cryo-electron tomogram of Rab5a-decorated vesicles
coated with VPS34 complex II–BATS. Scale bar 100 nm. b Subtomogram averaging reconstruction of human complex II–BATS bound to membrane-attached
Rab5a–GTP at 9.8 Å with the membrane masked-out. A model of human complex II based on the crystal structure of yeast complex II (5DFZ) was fit to the
density and refined with restraints. c Rab5a (PDB entry 3MJH) was optimally fit into the cryo-ET density. In this orientation, the Rab5a switch 2 helix faces
the VPS34 C2 insertion (C2HH). The Rab5a density is nestled between the C2HH, the VPS15 SGD and WD40 domains. d The crystal structure of the inactive
state of yeast complex II, in which the VPS15 kinase domain (N terminus coloured pink) contacts and inhibits the VPS34 kinase domain (activation loop
coloured green). e The cryo-ET structure of the active form of human complex II bound to membrane-attached Rab5a–GTP in the same orientation as d.
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HELCAT (helical and kinase domain48) is rotated in the cryo-ET
structure, released from the inhibitory grasp of the VPS15 kinase
domain (Fig. 5e), suggesting allosteric activation of complex II by
membrane coupled Rab5a. Similar allosteric activation of com-
plex I by binding NRBF2 was recently reported34. This indicates
that the activation mechanism of VPS34 complex II by Rab5a
involves both the increased recruitment of complex II by Rab5a to
membranes and the release of the autoinhibition.
The BARA domain in the adaptor arm attaches complex II to
membranes. The unmasked cryo-ET structure of complex
II–BATS shows a clear density corresponding to the membrane.
Interestingly, only the adaptor arm is solidly attached to the
membrane while the catalytic arm is poised above the membrane
(Fig. 6a, b). Lowering the density threshold shows that the density
of the protein complex is continuous with the outer membrane
leaflet (Fig. 6c). The BARA domain of Beclin 1 shows a protru-
sion towards the membrane, which is in direct contact with the
lipid bilayer. The Beclin 1 BARA domain contains a hydrophobic
loop (aromatic finger 1, residues FFW 359–361), which is critical
for membrane binding21,31,35,49,50. Thus, the loop was modelled
into the protrusion (Fig. 6a–c). Only a short extension at the
Beclin 1 BARA domain is visible in the cryo-ET density that
could correspond to the ATG14L BATS domain that was fused to
UVRAG to increase membrane occupancy (Fig. 6a).
All Rab GTPases have an unstructured C terminus called the
hypervariable region (HVR) before the cysteine motif for
prenylation and membrane anchoring51. The HVR of Rab5a is
not resolved, but its length of 34 residues could easily span the
distance of ~50 Å observed between the Rab density and the
membrane (Fig. 6b).
Complex II is present in a range of orientations on the lipid
bilayer. We next applied principal component analysis (PCA)
classification on wedge-masked difference maps52 to classify the
subtomograms according to the orientation of complex II–BATS
relative to the membrane (Supplementary Fig. 4c). Three of these
classes in which the complex can adopt a range of orientations
with respect to the membrane are shown in Fig. 6d and Sup-
plementary Movie 2. In all classes, the adaptor arm is the anchor
point at which the entire complex tilts relative to the membrane
and rotates around the adaptor arm. The tilting of the complex
could regulate the engagement with membranes by both arms of
the complex, while the rotations around the adaptor arm would
enable the catalytic arm to survey a larger membrane area for a
substrate lipid. This range of movement is mediated by the
flexible membrane anchoring of the Beclin 1 BARA domain.
Since the mean diameters of the LUVs for these three classes were
similar (80.0–83.4 nm) (Supplementary Fig. 4b), the motions of
the complex with respect to the membrane are not likely to be
caused by different membrane curvatures.
The VPS34 HELCAT has been shown to be able to completely
dislodge from complex I, and it was proposed that this movement
is essential for maximum activity, enabling the VPS34 HELCAT
to engage with PI, which would not be accessible in the classic V-
shape53. In our cryo-ET, the density for the kinase domain is
present in all classes having sharp features in the adaptor arm,
suggesting the ordered catalytic arm is a stable feature of the
active complex II bound to the Rab5a–GTP-decorated LUVs
(Supplementary Fig. 6b). Thus, instead of the HELCAT domain
dislodging to access the lipid bilayer, the cryo-ET suggests that
the whole complex tilts and rotates to reach the membrane. With
its adaptor arm flexibly bound to the lipid bilayer, the complex II
is able to explore an extensive range of orientations relative to the
membrane in order to bring the VPS34 HELCAT in close
proximity to its target PI.
Discussion
The cryo-ET structure of human complex II on Rab5a-coupled
membranes has revealed the Rab5 binding site on complex II and
elucidated key events associated with the activation of VPS34 by
Rab5a–GTP. Strikingly, Rab5a-decorated membranes induced
allosteric changes in the VPS34 HELCAT that release the VPS34
kinase domain from the inhibition by the VPS15 kinase domain
that was observed in the autoinhibited form of the yeast complex
II31 (Fig. 5d, e). This change in conformation of complex II after
associating with Rab5a on membranes is consistent with the
recent, elegant study of VPS34 complex II by single-molecule
kinetics that showed that Rab5a coupled to membranes both
increases the density of complex II on membranes and increases
the specific activity of complex II on Rab5a membranes relative to
membranes without Rab554. While it is clear that a significant
component of the increase in activity of complex I on Rab1a-
coupled membranes and complex II on Rab5a-coupled mem-
branes is due to enhanced recruitment, the conformational
changes in VPS34 seen in the cryo-ET suggest that activation
involves multiple steps. The structure shows that the adaptor arm
is tightly associated with the lipid bilayer whereas the catalytic
arm is poised above it, indicating that the catalytic arm carries out
catalysis and then detaches from the membrane (Fig. 6a, b). The
reconstruction demonstrates that this poised, active conformation
is the prevailing one. This might represent the predominant part
of the enzyme’s catalytic cycle, or it might have been stalled in
this state due to the lack of Mg/ATP in the cryo-ET material. This
intermediate conformation could imbue the enzyme complex
with properties in-between hopping and scooting catalysis55
where the scooting adaptor arm is tied to a hopping catalytic arm.
The structures suggest a three-state model of complex II activa-
tion by Rab5a–GTP (Fig. 6e).
Consistent with the organelle-specific roles of Rab5a on early
endosomes14,56,57 and Rab1 in autophagy30,58,59, we found that
Rab5a preferentially activates complex II over complex I, and
Rab1a activates only complex I. The cryo-ET structure shows that
the VPS15 WD40 and SGD domains, as well as the VPS34 C2
helical insertion (C2HH), make interactions with Rab5a (Fig. 5c).
However, it appears that the most extensive interface with the
Rab5a switch regions, which assume nucleotide-specific con-
formations, is the VPS34 C2HH. The C2HH interacts with both
switches I and II, while the VPS15 WD40 domain interacts with
Rab5a outside the switches. The VPS15 SGD interacts with the
surface of Rab5a opposite the switch interface. Rab1a makes
similar interactions with the VPS34 C2 helical insertion in
complex I (Fig. 3e). However, the VPS15 WD40 domain is greatly
shifted in complex I relative to complex II (Supplementary Fig. 7),
making it farther from the putative Rab1a interface, which is
consistent with the lack of changes in HDX for the complex I
WD40 upon Rab1a binding. This shift of the VPS15 WD40
appears to cause the VPS34 C2HH to tilt as it tracks the move-
ment of the WD40 domain. This might be part of the mechanism
for selectivity of complex I for Rab1a and complex II for Rab5a.
The complex-specific position of the WD40 domain may be
caused by the ATG14L or UVRAG unique domain that packs
against the WD40. Alternatively, it may be that there are direct
interactions of UVRAG or ATG14L with Rabs that are transient
and unobserved in our low-resolution reconstruction from cryo-
ET and are part of unobserved regions in HDX-MS analysis for
these subunits. Interestingly, the same C2HH mutant that
increases activation of complex II by Rab5a markedly reduces
activation of complex I by Rab1a, which could provide a tool to
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Fig. 6 The Beclin 1/UVRAG adaptor arm, together with Rab5a, mediates highly flexible membrane binding. a Subtomogram averaging density of
complex II–BATS bound to Rab5a–GTP decorated LUVs. Complex II directly attaches to membranes via its Beclin 1/UVRAG adaptor arm. The catalytic arm
hovers above the membrane with no direct contact. No density for the BATS domain is observed. b The distance between the Rab5a density and
membrane is ~50 Å, which easily can be spanned by the 34 residues forming the Rab5a HVR (not ordered in the structure). c The adaptor arm shows
density from the Beclin 1 BARA aromatic finger 1 (AF1) in contact with the outer membrane leaflet. Scale bar, 4 nm. d Three different classes from 3D
classification of Rab5a–GTP/complex II–BATS show different orientations relative to the membrane, however, the same complex II model with two ordered
arms and an active conformation of the VPS34 kinase domain can be fit to each class. While the adaptor arm stays bound to the membrane and serves as
an anchor point, complex II can tilt both up/down as well as sideways. e A three-state model for VPS34 complex II activation on membranes by Rab5
GTPases. Off membranes, the VPS34 kinase domain of complex II is autoinhibited by VPS15 (left). Binding of Rab5a–GTP to the adaptor arm recruits the
complex to membranes, releasing the auto-inhibitory interactions and enabling scooting via the adaptor arm state (middle). The complex is able to tilt up
and down so that the catalytic arm transiently engages the membrane to phosphorylate PI to synthesise PI3P (right). States 2 and 3 are able to scoot on the
membrane and thereby encounter new substrate.
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distinguish the contributions of the two complexes to various
cellular processes.
Although VPS34 was identified as a critical regulator of cellular
trafficking60 and a key Rab5 effector13 more than two decades
ago, the molecular basis for this remained completely unknown.
Our discoveries provide a structural and mechanistic view of how
Rab5a recruits and activates complex II on endosomes. Further-
more, we show that Rab1a can do the same for the autophagy-
specific complex I, through overlapping but distinct interactions
with the core VPS34/VPS15 subunits. This sheds light on the
mechanism of Rab1a involvement in autophagy, through a direct
activation of complex I. Together, these findings present a fra-
mework for future discovery of inhibitors targeting Rab-
dependent VPS34 activation for therapeutic purposes. Cryo-ET
enabled us to visualise the molecular organisation of Rab5a-GTP/
complex II assembly on membranes. The dynamic mode of
complex II membrane attachment allows the activated VPS34
kinase to survey the membrane for available substrate and gen-
erate local enrichment of PI3P that enables patterning of tightly
organised Rab-containing domains14 that ultimately determine
organellar identity.
Methods
Plasmids. Plasmids used in this study are listed in Supplementary Table 2.
Protein purification of human VPS34, complex I and complex II. For purifying
complexes I and II, Expi293F suspension cells (ThermoFisher A14527) were grown
at 37 °C, 8% CO2, and 125 rpm shaking in Expi293 Expression Medium (Ther-
moFisher A1435102). Plasmids at 1.1 mg/L culture were transfected into the cells at
a density of around 2.3 × 106/mL, using polyethylenimine (PEI) ‘MAX’ (Poly-
sciences 24765, 1 mg/mL in PBS) at 3 mg/L culture. Cells were grown at the same
condition as above for 48 h, then harvested at 3000 g for 25 min, flash-frozen in
liquid nitrogen, and stored at −80 °C, until they were used.
To prepare protein, the cells were suspended in 100mL/2 L cells of lysis buffer
(50mM HEPES, pH 8.0, 150mM NaCl, 1% Triton X-100 [Sigma, X100], 12%
glycerol, 0.5mM tris[2-carboxyethyl)]phosphine (TCEP, Soltec Ventures, M115),
2mMMgCl2, 1× EDTA-free inhibitor tablet (Roche, 05056489001), and incubated on
ice for 30min. The insoluble fraction was removed by centrifugation at 14,000 × g for
30min in a Ti45 rotor (Beckman Coulter). The supernatant fraction was incubated
with 2mL of IgG beads (GE Healthcare 17-0969-02) for 3.5 h. The mixture was
centrifuged at 1000 × g, and 100mL of supernatant was removed. The IgG beads were
transferred to a gravity flow column, and washed with 150mL of wash buffer (50mM
HEPES, pH 8.0, 150mM NaCl, 0.1% Triton X-100, 0.5mM TCEP, 5 mM ATP
[Sigma, A2383], 50mM MgCl2, 5 µg/mL RNaseA [Sigma, 83834]) and 150mL of
TEV buffer (50mM HEPES, pH 8.0, 150mM NaCl, 0.5mM TCEP). A 10mL aliquot
of TEV buffer and 80 µL of 4.4mg/mL TEV protease were added, and incubated at
4 °C overnight without rotation. The eluate was collected and beads were washed
three times with 5mL buffer each. The elution fractions were combined and
concentrated using a 100 kDa concentrator (Millipore, UFC910096) before running
on an S200 10/30 column equilibrated with 20mM HEPES, pH 8.0, 150mM NaCl,
0.5mM TCEP. The main peak fractions were pooled and concentrated. The proteins
were frozen in liquid nitrogen and stored at −80 °C. Human complex II was purified
in the same way as complex I except the NaCl concentration was 300mM throughout
the procedures. All complex I and II mutants were purified in the same way as WT
complex I and complex II, respectively.
Purification of human VPS34 was described previously21. In brief, a plasmid
pSM41 was expressed in bacteria (E. coli C41 (DE3)), purified using Ni-NTA
affinity chromatography with sonication buffer (10 mM Tris-HCl pH 8.0, 100 mM
NaCl, 10 mM imidazole), 1 Complete EDTA-free Protease Inhibitor Cocktail
Tablet (Roche, 11873580001), 0.1 mg/mL DNaseI, and 50 mL BugBuster (Novogen
70584), washed with Ni A1 buffer (20 mM Tris pH 8.0, 300 mM NaCl, 10 mM
imidazole, 2 mM β-mercaptoethanol), and Ni A2 buffer (20 mM Tris pH 8.0,
100 mM NaCl, 10 mM imidazole, 2 mM β-mercaptoethanol), and eluted with an
imidazole gradient with about 80 mL of Ni B1 buffer (20 mM Tris pH 8.0, 100 mM
NaCl, 300 mM imidazole, 2 mM β-mercaptoethanol). The His6 tag was cleaved
with TEV protease (made in house) and incubated overnight with gentle rocking at
4 °C, followed by purification on a HiTrap heparin column. The column was
washed with 20 mL HA buffer (20 mM HEPES pH 8.0, 100 mM NaCl, 2 mM
DTT), and the sample was eluted with 100 mL HB buffer (20 mM HEPES pH 8.0,
2 mM DTT, 1 M NaCl). The protein was further purified by gel filtration in 20 mM
HEPES pH 8.0, 100 mM NaCl, 2 mM DTT. The peak fractions were pooled and
concentrated to 5.2 mg/mL (51 μM).
Purification of p40-PX domain. Purification and labelling of the p40-PX domain
were described previously21. In brief, a plasmid pYO1125 was expressed in bacteria
(E. coli C41 (DE3)), sonicated in lysis buffer (20 mM HEPES pH 8.0, 200 mM
NaCl, 1 mM TCEP, 0.05 μL/mL universal nuclease (ThermoFisher, 88702), 0.5 mg/
mL lysozyme (MP Biomedicals, 195303)), affinity-purified with Glutathione
Sepharose resin, washed with 100 mL wash buffer (20 mM HEPES pH 8.0, 300 mM
NaCl, 1 mM TCEP) and 100 mL TEV buffer (20 mM HEPES pH 8.0, 200 mM
NaCl, 1 mM TCEP). The N-terminal GST tag was cleaved with TEV protease and
incubated overnight with gentle rocking at 4 °C. The elution fractions were col-
lected and concentrated in a 10000 MWCO Amicon Ultra15 concentrator (Mil-
lipore, UFC901024). The concentrated protein was further purified by gel filtration
on a Superdex 75 16/60 column (GE Healthcare 17-1068-01), in a buffer containing
20 mM HEPES pH 8.0, 200 mM KCl, 1 mM TCEP. The peak fractions were pooled
and concentrated to 23.5 mg/mL (1.35 mM). The purified PX domain was labelled
using AF647 C2 Maleimide kit (Life Technologies, A20347), and the labelled
protein was purified using a heparin column.
Purification of human Rab5a. For the human Rab5a construct that was used for
maleimide labelling, a WT Rab5a (1–212) fragment was mutated into Q79L, also
surface-exposed cysteines were mutated to serines (C19S-C63S) so that one
cysteine was left at the C terminus of the protein (plasmid pOP823 His-SUMO-
Rab5a(1–212)-Q79L-C19S-C63S). Protein was overexpressed in E. coli C41(DE3)
RIPL purified by Ni-NTA FF columns (GE Healthcare 17-5255-01), followed by
the removal of the His-tag with SUMO protease, dialysis overnight (10 kDa
MWCO, SnakeSkin™ ThermoFisher) and another passage through Ni-NTA resin.
The flow-through was concentrated and mixed with 11 molar excess of GTP (Jena
bioscience NU-1012) or GDP (Jena bioscience NU-1172) and 18 molar excess of
EDTA for 90 min at room temperature. The MgCl2 was then added to 36 molar
excess and incubated for another 30 min. The mixture was loaded on a size-
exclusion chromatography and the peak fractions were concentrated to ~0.5–1 mM
in 25mM HEPES pH 7.0, 150 mM NaCl, 0.5 mM tris-(2-carboxyethyl) phosphine
(TCEP).
For HXD-MS, a Rab5a-Q79L construct was designed with last 4 residues
(CCSN) deleted (plasmid pYO1261 His-SUMO-Rab5a(1-211)-Q79L) and was
purified as above.
Purification of human Rab1a. For the human Rab1a construct (plasmid pJB78
GST-TEV-Rab1a(1–204)-Q70L-C26S-C126S) that was used for maleimide label-
ling, a WT Rab1a (1–204) fragment was mutated into Q70L also the surface-
exposed cysteines were mutated to serines (C26S-C126S) so that only one Cys was
left at the C terminus of the protein. Protein was overexpressed in E. coli C41(DE3)
RIPL, purified on Glutathione Sepharose 4B resin (GE Healthcare 17-0756-05),
followed by the removal of the GST tag with TEV protease overnight. The cleaved
protein was diluted to a final concentration of 50–100 mM NaCl in dilution buffer
(20 mM HEPES 8.0 and 1 mM TCEP) and passed through a 5 mL HiTrap Q
column (GE Healthcare, 17505301) followed by a 5 mL HiTrap Heparin column
(GE Healthcare, 17040601) to remove cleaved GST and TEV protease. The heparin
flow-through was concentrated, loaded with nucleotide and MgCl2, purified and
concentrated in the same way as Rab5a.
For HXD-MS, a Rab1a–Q70L construct was designed with last 2 residues (CC)
deleted. This construct (plasmid pYO1262 His-TEV-Rab1a(1-203)-Q70L) was
expressed and purified by affinity chromatography on Ni-NTA, ion-exchange
chromatography on Q column and Heparin column and gel filtration on Superdex
75 16/60.
Synthesis of BrCO6K. We synthesised BrCO6K for incorporation into Rab5a
using the scheme illustrated in Supplementary Fig. 8. 4-Bromobutan-1-ol (1.0 g,
6.5 mmol, 1 eq.) was dissolved in anhydrous dichloromethane (DCM) (13 mL) and
cooled to 0 °C in an ice bath. N,N′-disuccinimidyl carbonate (2.0 g, 7.9 mmol, 1.2
eq.) and DIPEA (2.3 mL, 13.0 mmol, 2 eq.) were added at 0 °C. The reaction was
allowed to warm up to room temperature and was stirred for 4 h until thin layer
chromatography (TLC) showed full conversion of the starting material. Then
anhydrous tetrahydrofuran (THF) (13 mL) and α-Boc-Lys-OH (1.9 g, 7.9 mmol,
1.2 eq.) were added and the reaction was stirred overnight at rt. The reaction
mixture was diluted with DCM and the organic phase was washed twice with 10%
citric acid and once with brine and the combined organic phase was dried over
Na2SO4. The solvent was removed under reduced pressure and the crude product
was purified by flash column chromatography (DCM:MeOH = 97:3+ 0.25% acidic
acid). 1.6 g (57% yield) α-BocBrCO6K were isolated as light yellow oil.
1H NMR (500MHz, DMSO-d6) δ= 7.07 (t, 3J= 5.7 Hz, 1H), 7.00 (d, 3J= 7.9
Hz, 1H), 3.95 (t, 3J= 6.5 Hz, 2H), 3.88–3.77 (m, 1H), 3.55 (t, 3J= 6.6 Hz, 2H), 2.93
(q, 3J= 6.6 Hz, 2H), 1.84 (p, 3J= 6.8 Hz, 2H), 1.70–1.49 (m, 4H), 1.42–1.23 (m,
13H) ppm.
13C NMR (75MHz, MeOD) δ= 176.2, 159.1, 158.2, 80.5, 64.8, 54.8, 41.4, 33.9,
32.4, 30.6, 30.5, 28.9, 28.7, 24.1 ppm.
MS(ESI), m/z calced. for C16H29BrN2O6: 424.12 (for 79Br), 426.12 (for 79Br);
found: 447.1 [M+Na]+ (for 79Br), 449.1 [M+Na]+ (for 81Br).
α-Boc-BrCO6K (1.6 g, 3.7 mmol, 1 eq.) was dissolved in DCM (40mL) and
TFA (40 mL) was added. The reaction was stirred overnight at room temperature
and the solvent was removed under reduced pressure. The crude product was
dissolved in methanol (2 mL) and the solution added dropwise to cold diethylether
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(−20 °C, 80 mL). The suspension was centrifuged at 3234 g at 4 °C, the supernatant
was discarded and the solid was collected, resuspended and again washed with cold
diethylether, twice. The product was dried on air and 0.87 g (72% yield) BrCO6K
were isolated as a light brown solid.
Site-specific incorporation of BrCO6K into Rab5a in bacteria. BrCO6K was
synthesised as described above. In contrast to previously reported BrC6K24,
BrCO6K bears a carbamate moiety linking the ε-amino group of lysine to the
bromoalkyl functionality, making it stable against the E. coli deacylase CobB. The
expression of Rab5a (plasmid STp6, pBAD_Rab5a_Q79L_1-
212_C19S_C63S_S84TAG-His6) with site-specifically incorporated BrCO6K was
carried out as described previously24. Protein was overexpressed in DH10B cells
(Invitrogen, 18290015) and purified by Ni-NTA FF columns (GE Healthcare 17-
5255-01). The protein was concentrated, loaded with nucleotide/MgCl2 as descri-
bed above and further purified size-exclusion chromatography. The peak fractions
were concentrated to ~0.5–1 mM in 25 mM HEPES pH 8.0, 150 mM NaCl, 0.5 mM
tris-(2-carboxyethyl) phosphine (TCEP).
Crosslinking of Rab5a S84BrCO6K to VPS34 and complex II. Purified complex
II was mixed with 50–100 molar excess of purified Rab5a S84BrCO6K in 5–15 μL
reaction volume. VPS34 was mixed with 100–200 molar excess of Rab5a
S84BrCO6K in 5–15 μL reaction volume. Both samples were incubated overnight at
4 °C and then analysed by SDS-PAGE. The gel bands of crosslinked products were
cut out and analysed by mass spectrometry.
The excised gel bands were digested as described previously with minor
modifications61. Trypsin was prepared in the digestion buffer (45 mM ammonium
bicarbonate, 10% acetonitrile, v/v) at a concentration of 5 ng/μL. The digestion was
incubated at 37 °C for 15 h. Resulting peptides were de-salted using C18
StageTips62.
Liquid chromatography–tandem mass spectrometry (LC–MS/MS) analysis was
performed using an Orbitrap Fusion Lumos Tribrid mass spectrometer
(ThermoFisher Scientific), connected to an Ultimate 3000 RSLCnano system
(Dionex, ThermoFisher Scientific). Peptides were injected onto a 50-cm EASY-
Spray C18 LC column (ThermoScientific) that is operated at 50 °C column
temperature. Mobile phase A consists of water, 0.1% v/v formic acid and mobile
phase B consists of 80% v/v acetonitrile and 0.1% v/v formic acid. Peptides were
separated using a linear gradient going from 2% mobile phase B to 40% mobile
phase B over 110 min, followed by a linear increase from 40 to 95% mobile phase B
in 11 min. Peptides were loaded and separated at a flow rate of 0.3 μL/min. Eluted
peptides were ionised by an EASY-Spray source (ThermoScientific) and introduced
directly into the mass spectrometer. The MS data is acquired in the data-dependent
mode with a 3-s acquisition cycle. The full scan mass spectrum was recorded in the
Orbitrap with a resolution of 120,000. The ions with a charge state from 3+ to 7+
were isolated and fragmented using higher-energy collisional dissociation (HCD).
For each isolated precursor, one of three collision energy settings (26%, 28% or
30%) was selected for fragmentation using data-dependent decision tree based on
the m/z and charge of the precursor. The fragmentation spectra were then recorded
in the Orbitrap with a resolution of 50,000. Dynamic exclusion was enabled with a
single repeat count and 60-s exclusion duration.
The MS2 peak lists were generated from the raw mass spectrometric data files
using the MSConvert module in ProteoWizard (version 3.0.11729). The default
parameters were applied, except that Top MS/MS Peaks per 100 Da was set to 20
and the de-noising function was enabled. Precursor and fragment m/z values were
recalibrated. Identification of cross-linked peptides was carried out using
xiSEARCH software (https://www.rappsilberlab.org/software/xisearch)63. For
crosslinked Rab5a S84BrCO6K-VPS34 sample, the peak list was searched against
the sequences and the reversed sequences of Rab5a and VPS34, and for crosslinked
Rab5a S84BrCO6K-complex II sample, the peak list was searched against the
sequences and the reversed sequences of Rab5a and all subunits of complex II. For
both cases, BrCO6K (residue 84) was defined as a modified lysine residue
(Kbrco6k) in the Rab5a sequence file. The crosslinking specificity was defined
between BrCO6K and any cysteine, lysine, histidine, aspartate and glutamate
residues. The following parameters were applied for the search: MS accuracy = 4
ppm; MS2 accuracy = 10 ppm; enzyme = trypsin (with full tryptic specificity);
allowed number of missed cleavages = 4; missing monoisotopic peak= 2; fixed
modifications = carbamidomethylation on cysteine; variable modifications =
oxidation on methionine. All crosslink-spectrum matches (CSMs) that were
autovalidated by xiSEARCH were further manually inspected and validated. No
CSM against the reversed protein sequences (decoy matches) were autovalidated. A
list of identified cross-linked peptide pairs is reported in Supplementary Table 1
and an annotated fragmentation spectrum can be seen in (Supplementary Fig. 9).
Hydrogen/deuterium exchange mass spectrometry (HDX-MS). Complex II
(5 μM) alone and a mixture of complex II (5 μM) with 30 μM Rab5a-Q79L-GTP
were incubated for ~30 min at room temperature. An aliquot of 5 μL of complex II
alone was exposed to 45 μL of D2O Buffer only (25 mM HEPES pH 8.0, 50 mM
NaCl, 1 mM TCEP and D2O at 94.2% final concentration (D2O, Acros Organics
351430075)) for a defined period of time at room temperature. Furthermore, an
aliquot of 5 μL complex II (5 μM) with 30 μM Rab5a-Q79L-GTP exposed to 45 μL
D2O Buffer + Rab5 (25 mM HEPES pH 8.0, 50 mM NaCl, 1 mM TCEP, 30 μM
Rab5a–GTP and D2O at 94.2% final concentration) for a defined period of time at
room temperature. The final D2O sample concentration was 84.8% D2O. Four
time-points were produced (3/30/300/3000 s), with each exchange reaction exe-
cuted in triplicate. The exchange reaction was quenched using 20 μL of ice-cold
5 M guanidinium chloride, 15 mM TCEP, and 8.4% formic acid, pH 1 in UPLC
grade H2O (Romil, H949). The final pH of the sample was 2.2. Each sample was
immediately flash-frozen in liquid nitrogen and subsequently stored at −80 °C
until analysis.
Complex I (7 μM) alone and a mixture of complex I (7 μM) with 28 μM
Rab1a–Q70L–GTP were incubated for 10 min at room temperature. An aliquot of
5 μL of this stock solution was mixed with 40 μL of D2O buffer (consisting of
20 mM HEPES pH 8.0, 150 mM NaCl, 0.5 mM TCEP in D2O, final concentration
94.7%) for a defined period of time at room temperature. The following procedures
are essentially the same as complex II+ Rab5a.
Samples were quickly thawed and manually injected on an M-Class Acquity
UPLC with HDX Manager technology (Waters) set to maintain a constant
temperature of 0.1 °C. Proteins were digested using an in-line Enzymate
Immobilised Pepsin Column (Waters) at 15 °C for 2 min, and were collected on a
van-guard pre-column trap (Waters). Digested peptides were eluted from the trap
onto an Acquity 1.7 μm particle, 100 mm × 1mm C18 UPLC column (Waters),
equilibrated in Pepsin-A buffer (0.1% formic acid), using a 5–36% gradient of
Pepsin-B buffer (0.1% formic acid, 99.9% acetonitrile) over 26 min. Peptide data
were collected using a Waters Synapt G2 Si (Waters) over a 50–2000m/z range
using the High-Definition MSe data acquisition mode fitted with an ESI source.
Peptide identification was done with ProteinLynx Global Server (PLGS, Waters,
UK). Peptides were identified from four non-deuterated samples for complex I, and
three non-deuterated samples for complex II. Deuterated peptides were analysed by
DynamX 3.0 software (Waters, UK). Peptide inclusion criteria was a minimum
score of 6.4, a minimum of 0.3 products per amino acid, a maximum MH+ error
of 5 ppm, and a positive identification meeting these criteria in at least 2 of the 3
non-deuterated files. An initial automated spectral processing step was conducted
by DynamX followed by a manual inspection of individual peptides for sufficient
quality. A table of every peptide included within the dataset and the quality
assessment statistics of the dataset are available in Supplementary Data 1 and 2.
The HDX-MS analysis in this manuscript complies with the community agreed
guidelines64.
GUV assays and Rab labelling of GUVs. A lipid mixture was assembled
according to Supplementary Table 3. The procedures for GUV generation and
immobilisation on an observation chamber were described previously21. For GUV
generation, a 15 μL aliquot of a 1 mg/mL GUV lipid mixture in chloroform was
placed onto the Indium-Tin-Oxide (ITO)-coated side of an ITO slide (Nanion)
then dried in a desiccator for 1 h. GUVs were made in the presence of 220 μL of
swelling solution (0.5 M sucrose), using a GUV maker (Vesicle Pro, Nanion) with a
programme at 10 Hz; 60 °C; 1 Amp; 3 min rise; 68 min fall. After GUVs were
produced, they were immediately removed from the slide and transferred to a
1.5 mL tube, which had been coated with 5 mg/mL BSA (Sigma A7030) for 1 h then
rinsed once with a swelling solution. For GUV immobilisation, wells of an eight
well glass bottom chamber (Ibidi 80827) were coated with 100 μL of avidin solution
(0.1 mg/mL avidin egg white, Life Technologies A2667 dissolved in PBS, and 1 mg/
mL BSA) for 15 min, then washed two times with observation buffer (25 mM
HEPES pH 8.0 and 271.4 mM NaCl). An aliquot of observation buffer was added to
the wells, followed by the addition of the GUVs. Rabs (with a C-terminal Cys) were
incorporated onto GUVs by adding 10 μM of Rab (fourfold molar excess over
MCC-PE lipid) to the immobilised GUVs and incubating at 4 °C overnight.
Unbound Rabs were removed by carefully adding and taking off 360 μL wash
buffer five times (31.8 mM HEPES pH 8.0, 172.7 mM NaCl, 5 mM β-mercap-
toethanol, and 181.8 mM sucrose). The kinase reaction, microscopy, and image
analysis were described previously21. GUVs were observed with a ×63 oil
immersion objective (Plan-Apochromat ×63/1.40 Oil DIC, Zeiss) on an inverted
confocal microscope (Zeiss 780), using ZEN software (Zeiss). The observation
chamber was immobilised on a microscope stage holder using an adhesive (Blu-
Tack, Bostik). In the ZEN software, Time Series and Positions were selected. The
Lissamine-rhodamine channel for GUVs was excited with a Diode-pumped solid-
state (DPSS) 561 nm laser and collected with a 566–629 nm band. The Alexa Fluor
488 channel for the secondary antibody was excited using an Argon multiple 458,
488 and 514 nm laser, and collected with a 500–530 nm band. Reaction progress
curves for the kinase assays with SDs for each time point are shown in Supple-
mentary Fig. 10.
For Rab5 immunostaining on the GUVs, rabbit Anti-Rab5 Antibody (#2143S
Cell Signalling) was added after Rab labelling at 1:100 dilution and left overnight at
4 °C. Unbound primary antibodies were removed by adding and taking off 360 μL
wash buffer four times. Goat anti-rabbit secondary antibody Alexa Fluor 488
(ThermoFisher Catalogue #: A-11008) was added at 1:250 dilution and incubated
for 2 h at room temperature. Unbound secondary antibodies were removed by
adding and taking off 360 μL wash buffer four times.
LUV preparation. A lipid mixture was assembled according to Supplementary
Table 3 and dried under nitrogen gas. The glass vial was rotated so that a thin film
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was formed on the glass wall. The remaining solvent was evaporated under vacuum
for 1 h. The lipids were dissolved in lipid buffer (25 mM HEPES pH 8.0, 150 mM
NaCl, 1 mM TCEP or for maleimide reactions in 25 mM Hepes pH 7.0, 150 mM
NaCl) and vortexed for 2 min. The solution was transferred to a 1.5 mL Eppendorf
tube and sonicated for 2 min in a bath sonicator. After 10 cycles of freeze/thaw in
liquid nitrogen and a 43 °C water bath, the lipid mixture was extruded at least 20
times through a 100 nm filter for flotation assays (Whatman Anotop 10 syringe
filter 0.1 μm pore size, 10 mm diameter, Cat No 6809-1112) or 50 nm filter for
cryo-ET (NanoSizer MINI Liposome Extruder, Part Code: TT-001-0010). The lipid
solution was then used fresh.
Rab immobilisation on LUVs. The LUVs included Lissamine Rhodamine (0.2%)
in order to measure the LUV concentration throughout the LUV preparation by
measuring the emission (ex 560/em 583) on a plate reader (PHERAstar BMG
LABTECH). To ~3 mM LUVs (containing 0.2 mM or 6% PE-MCC), Rab was
added in 0.3–0.6× molar ratio to PE-MCC lipid in 25 mM Hepes pH 7.0, 150 mM
NaCl. After overnight incubation in the fridge, the reaction was spun for 5 min at
5000 × g to remove any precipitate. Then, LUVs were pelleted by centrifuging the
supernatant for 30 min at 60,000 × g at 4 °C in a TLA 100 rotor (Beckman Coulter).
After the spin, the supernatant, which has unreacted Rab, was taken off and the
clearly visible pellet containing LUVs was re-dissolved in the buffer (25 mM Hepes
pH 8.0, 150 mM NaCl, 1 mM TCEP) and the final LUV concentration was
determined by Lissamine Rhodamine emission.
Flotation assay. The mixture of proteins and lipids contained 1.8 mM (~1.5 mg/
mL) LUVs and 2 μM VPS34 complex in buffer containing 25 mM HEPES pH 8.0,
150 mM NaCl and 1 mM TCEP. The total sample volume was 20 μL. While the
LUVs and proteins were incubated on ice for 30 min, a sucrose gradient was
prepared. For the gradient, several sucrose solutions were layered from the bottom
to the top in a Beckman centrifuge tube (343775 Thickwall Polycarbonate Tube,
Beckman Coulter): 40 μL 30% sucrose solution, 52 μL 25% sucrose solution, 52 μL
20% sucrose solution. Then 16 μL of the LUV/protein sample was carefully
pipetted on top of the gradient. From the remaining LUV/protein sample, 2.5 μL
were kept as an input sample for the SDS-PAGE. The gradient was then cen-
trifuged for 3 h in a TLS-55 rotor (Beckman Coulter) at 258,500 × g at 4 °C.
Afterwards, 6 fractions of 26 μL each were carefully collected from the top of the
gradient. The input and gradient fractions were analysed by SDS-PAGE.
MitoID. The MitoID experiments were performed following the methods pre-
viously described28. Briefly, two confluent T175 flasks of HEK293T cells were
transfected with the Rab-BirA*-HA-MAO chimeras for 24 h, after which exo-
genous biotin was added for another 16 h. Cells were then washed and lysed, using
25 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% (v/v) Triton X-100, 1 mM
PMSF, and 1 cOmplete protease inhibitor cocktail tablet (Roche) per 50 mL buffer.
After 30 min of incubation, the lysate was added to washed MyOne Streptavidin
Dynabeads (Invitrogen) and left to rotate at 4 °C overnight. After ~16 h, beads were
repeatedly washed in Wash Buffer 1 (2% SDS and cOmplete protease inhibitors),
Wash Buffer 2 (1% (v/v) Triton X-100, 0.1% (w/v) deoxycholate, 500 mM NaCl,
1 mM EDTA, 50 mM HEPES or Tris pH 7.4 and cOmplete protease inhibitors),
and Wash Buffer 3 (50 mM Tris pH 7.4, 50 mM NaCl, and cOmplete protease
inhibitors). Finally, the beads were eluted in SDS sample buffer and 3 mM biotin by
incubating for 3 min at 98 °C, after which 1 mM β-mercaptoethanol was added.
Samples were analysed by tandem LC–MS/MS mass spectrometry, as described28,
as well as loaded onto a Tris-Glycine gel and transferred onto nitrocellulose paper.
Western blots were blocked in 5% (w/v) milk and probed with primary and sec-
ondary antibodies, all for 1 h each and with 0.01% PBS-Tween-20 washes in
between. The antibodies used were mouse anti-HA (supernatant from hybridoma
clone 12CA5 used at a dilution of 1:250), rabbit anti-VPS15 (Proteintech, 17894-1-
AP, dilution 1:1000), rabbit anti-VPS34 (Protein-tech, 12452-1-AP, dilution
1:1000), rabbit anti-Beclin 1 (Santa Cruz Biotechnology, sc-11427, lot #H3012,
dilution 1:1000), rabbit anti-ATG14L (Cell Signaling Technology, 5504S, dilution
1:750), and rabbit anti-UVRAG (Cell Signaling Technology, 5320S, dilution
1:1000). Uncropped western blots can be seen in Source Data for Fig. 3a.
Cell culture and confocal microscopy. HEK293T cells were grown in DMEM
medium (Life Technologies, 31966047) containing 10% FBS (ThermoFisher,
10270106) and 1% Pen–Strep (Gibco, 15140122) at 37 °C with 5% CO2 until
60–70% confluency. After stripping the cells using 0.05% trypsin in 0.5 mM EDTA,
the cell density was measured by a cell counter (ThermoFisher, AMQAX1000),
then adjusted to 0.3 × 106/mL in the same medium. Diluted cells (0.5 mL) were
grown on a coverslip in a well of a 24-well plate (Corning, 3526) for 24 h at 37 °C
with 5% CO2. The medium was replaced with pre-warmed Opti-MEM medium
(ThermoFisher, 11058021) containing 10% FBS, and grown for 6 h at 37 °C with
5% CO2 for DNA transfection.
Cells were transfected with 1.1 μg/mL plasmid DNA and 3.3 μg/mL
polyethylenimine (PEI) ‘MAX’ (Polysciences 24765, 1 mg/mL in PBS). The
concentration of each plasmid for multiple subunits was initially adjusted to
100 ng/μL in PBS, then equal amount of DNA was mixed to make up to 1.1 μg/mL.
The DNA and PEI were mixed in 20 μL PBS (total volume) for 5 min at RT, then
added to the cells, and incubated for 18–24 h at 37 °C with 5% CO2.
Cell were fixed with 4% paraformaldehyde at RT for 10 min, washed once with
PBS, permeabilised with 0.05% digitonin at RT for 10 min, then washed three times
with PBS. The coverslips were located upside down on a slide glass which had been
spotted with a mounting medium (Vector Laboratories, H-1000). The coverslips
were immobilised by nail varnish. Cells were observed using an inverted confocal
microscope (Zeiss 780) with a ×63 oil immersion objective (Plan-Apochromat ×63/
1.40 Oil DIC, Zeiss) using ZEN software (Zeiss). The mCherry channel was exited
with a Diode-pumped solid-state (DPSS) 561 nm laser and collected with a
600–630 nm band. The EGFP channel was excited with an Argon multiple 458, 488
and 514 nm laser, and collected with a 500–530 nm band. Micrographs were
analysed by Fiji and Adobe Photoshop (Adobe).
For the quantification of VPS34-GFP localisation at the mCherry-Rab peak
position in the transects in Figs. 2e and 4e, the value in the GFP channel at the
mCherry-Rab peak was divided by the mean background in the GFP channel for
3–10 regions outside the peak area. More than three fields of cells and n= 15 cells
were included for each analysis. The image analysis was done using Fiji (ImageJ),
Microsoft Excel, and GraphPad Prism7.
Cryo-ET and subtomogram averaging. LUVs were labelled with Rab5a–GTP as
described above. For grid preparation, LUVs were mixed with complex II–BATS
and incubated on ice for 30–45 min. BSA-coated gold fiducials (Gold nanoparticles
10 nm, BBI Solutions EM.GC10) were then added up to the final volume of 3 μL
and mixed (6 mg/mL LUVs and 16 μM complex II–BATS, final concentrations).
The 3 μL samples were applied immediately to multi-hole grids (Multi A (various
hole sizes, carbon film), Grid: Au, Mesh: 300, QUANTIFOIL). The grids were glow
discharged for 30 s with the Quorum SC7620 glow discharger prior to use. The
samples were plunge-frozen in liquid ethane cooled by liquid nitrogen inside a
Vitrobot (FEI, ThermoFisher). Blotting papers were left at least for 30 min in 100%
humidity at 18 °C. The Vitrobot blot force was 20, with a blot time of 6 s.
Tomogram acquisition for complex II–BATS on Rab5a–GTP decorated
membranes was performed on an FEI Titan Krios electron microscope
(ThermoFisher Scientific) operated at 300 kV with a Gatan Quantum energy filter
(slit width 20 eV) and a K3 direct detector operated in counting mode. Serial-EM
software was used to acquire each tilt series using a dose-symmetric scheme with a
tilt range ± 60°, 3° angular increment and defoci from −2 to −5 μm65,66. Each tilt
series of 41 10-frame movies was recorded in counting mode with a pixel size of
2.133 Å/px at a dose rate of ~5.5 e−/Å2/s and a total dose per tomogram of ~123 e
−/Å2. A total of 115 tilt series were collected over 2 days. Data collection
parameters are summarised in Supplementary Table 4.
The raw movies were corrected for detector gain pixel defects and aligned using
‘alignframes’ from the IMOD package67 (installed using Python 3.7). Tilt series that
could not be aligned during gold fiducial alignment or had contamination such as
dirt or ice were discarded. Tilt-series were low pass filtered according to the
cumulative radiation dose68 and aligned using gold fiducial markers in the IMOD
package. Bin8 (pixel size 17.064 Å/px) and bin4 (pixel size 8.532 Å/px) non-
contrast-transfer-function (CTF) corrected tomograms were reconstructed by
weighted back-projection in IMOD. 3D CTF-correction for bin2 (pixel size 4.266
Å/px) and bin1 (pixel size 2.133 Å/px) tomograms were performed using NovaCTF
phaseflip69 with defocus estimation by ‘ctfplotter’ from the IMOD package.
EMAN2.2 was used for converting map formats.
Subtomogram alignment and averaging were done as previously described37,70
using the subTOM package written with MATLAB (MathWorks) functions adapted
from the TOM71, AV372 and Dynamo packages73. The scripts and relevant
documentation are available to download [https://www2.mrc-lmb.cam.ac.uk/
groups/briggs/resources] and [https://github.com/DustinMorado/subTOM/releases/
tag/v1.1.4]. Additionally, instead of a binary wedge mask, a modified wedge mask
was used70. The missing wedge was modelled at all processing stages as the sum of
the amplitude spectra of subtomograms extracted from regions of each tomogram
containing empty ice, and was applied during alignment and averaging.
To define the initial subtomogram positions, a plugin for Chimera was used to
set centres and radii of vesicles, which had a dense protein coat, in 105 bin8
tomograms74. A wide range of sizes of vesicles was used in the analyses, and only
vesicles with invaginations or large deformities were omitted. The subtomogram
coordinates (x/y/z) and initial Euler angles (but random in-plane rotation) were
defined by the sphere surface with a uniform sampling of 8 px (~136 Å). As vesicles
are not perfectly spherical, subtomograms were first aligned to the vesicle lipid
bilayer with a reference containing a membrane bilayer. The vesicle diameters were
determined by calculating the vesicle centroid by the average position of the
subtomograms around each vesicle after membrane alignment. Then an average
diameter was calculated by measuring the distance of each subtomogram to the
calculated centroid and multiplied by two. The distance between the protein
complex and membrane (~6 nm) was subtracted from the calculated diameter. To
identify particles, subtomograms were aligned to an initial reference consisting of
two gaussian-filtered ellipsoids forming a V-shape (Supplementary Fig. 6a,
reference). After aligning against the V-shape, some subtomograms converged and
formed clusters, which indicated the presence of a particle (Supplementary Fig. 6a,
A). The subtomogram coordinates were cleaned by a minimal distance threshold
(distance cutoff 8 px, cluster size 2, cluster distance 2 px) and cross-correlation
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cutoff so that 191,169 particles remained (Supplementary Fig. 6a, B).
Subtomograms extracted from the very top and bottom of the vesicles, where they
contact the air-water interface, were excluded by the cross-correlation cutoff.
Subtomograms were split into even/odd halves in bin4 and further aligned
separately until the resolution did not improve (Supplementary Fig. 6a, C). In order
to analyse the heterogeneity of the subtomograms, a principal component analysis
(PCA) classification on wedge-masked difference maps was used to classify the
protein complex region within the subtomograms52. For the PCA, a cylindrical
mask was applied that encompassed the protein density and excluded the
membrane density. The first 5 eigencomponents were used to sort the data into 20
classes (Supplementary Fig. 6b). Of the 20 classes, classes 1–6 showed the most
distinct features as well as the presence of the membrane and were combined to a
total of 26,979 particles and further aligned in bin4 (Supplementary Fig. 6a, D). The
alignment was then continued in bin2, where the subtomograms were shifted to the
centre of the box, and bin1 until no improvement in resolution could be achieved
(Supplementary Fig. 6a, E and F). The local resolution calculated in Relion 3.075
showed a range of 8–16 Å with an overall resolution of 9.8 Å (FSC 0.143 cutoff)
(Supplementary Fig. 5). Additionally, the LAFTER algorithm was used for local de-
noising of the final maps76. In order to classify the complex according to its
orientation relative to the membrane, another PCA classification was performed on
bin4 subtomograms, applying a cylindrical alignment mask that encompassed the
membrane density and excluded the protein density. Classes 1–3 were subsequently
further aligned in bin2.
Model building. As no map coordinates have been deposited for the cryo-EM
structures by Chang et al. or Young et al., we have used the SWISSMODEL
homology-modelling server41 and the crystal structure of yeast complex II (PDB:
5DFZ) to generate an initial model. UCSF Chimera77 was used for rigid-body
fitting and visualisation. Following this, the kinase domains of the complex II
subunits were adjusted with Coot as rigid bodies to fit the EM density78. An initial
model for the human VPS34 HELCAT was built starting with PDB ID 3IHY. PDB
entry 4DDP was used as an initial model for the human Beclin 1 BARA domain50.
PDB ID 3MJH provided an initial model for the Rab5a47. Some manual adjust-
ments were made to fit the density using Coot45,78,79, then the structure was
regularised and fit to the density using REFMAC42–45. Finally, the model of
complex II was refined using molecular dynamics in ISOLDE/ChimeraX46,80, while
manually adjusting the model to improve the geometry and fit to the density. The
model was subsequently refined with REFMAC. Prior to our work reported here,
the only structure that was reported for a human VPS34 complex with both arms
of the V-shaped complex ordered was the cryo-EM reconstruction of the NRBF2
MIT domain in a complex with VPS34 complex I34. Although It was reported that
the yeast complex II could be fit into the density for this complex I reconstruction,
no coordinates were deposited. Consequently, we fit a model for complex I into the
complex I cryo-EM density (EMD-20390). This required some manual readjust-
ment of the model, using the programme COOT78,79 followed by REFMAC
refinement with PROSMART42 restraints to improve the geometry. This model of
complex I enabled us to better interpret the HDX-MS observations that suggest
how Rab1a interacts with complex I.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The cryo-ET structure and a representative tomogram are deposited in the Electron
Microscopy Data Bank (EMDB) under accession codes EMD-12214 (3D cryo-ET map
with the membrane masked-out before B-factor sharpening in LAFTER), EMD-12237 (a
reconstruction in which the lipid membrane was not masked-out before sharpening in
LAFTER) and EMD-12238 (a sample non-CTF-corrected bin4 tomogram). The
associated molecular model is deposited in the protein data bank (PDB) under accession
codes 7BL1. Protein structures from published work that were used in this study are
available in the PDB under accession codes: 5DFZ, 3IHY, 4DDP and 3MJH. CLMS data
were deposited to ProteomeXchange (aka PRIDE) (accession code PXD023533) and
jPOST (accession code JPST001056). The MATLAB package subTOM is available for
download from https://www2.mrc-lmb.cam.ac.uk/groups/briggs/resources and https://
github.com/DustinMorado/subTOM/releases/tag/v1.1.4. All reagents generated by this
study are available from the corresponding authors on request. Source data are provided
with this paper.
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